Intellectual Property

Pharmaceutical products are known for the lengthy period required from drug discovery to the New Drug Application for approval, which may take a dozen years or so, as well as the very low success ratio for commercialization and the enormous investment amount required. In addition, there is usually only one basic patent that covers one pharmaceutical product, while remarkable amount of licensing fee is necessary when licensing in a product from the outside party. Moreover, the patent situation can be a key determining factor during the discussion on the feasibility study of individual product. Therefore, it is indispensable to focus on the effective utilization of intellectual property.

Takeda pursues strategic and international intellectual property strategies, which are seamlessly integrated with the other functions of research, development, production, sales, and alliance, thereby maximizing the value of its in-house ethical drugs.

Intellectual Property Strategy at Takeda

Changes in the Royalty Income